These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

606 related items for PubMed ID: 30269140

  • 1. Diagnostic Performance of Radiolabeled Prostate-Specific Membrane Antigen Positron Emission Tomography/Computed Tomography for Primary Lymph Node Staging in Newly Diagnosed Intermediate to High-Risk Prostate Cancer Patients: A Systematic Review and Meta-Analysis.
    Kim SJ, Lee SW, Ha HK.
    Urol Int; 2019; 102(1):27-36. PubMed ID: 30269140
    [Abstract] [Full Text] [Related]

  • 2. Diagnostic Accuracy of F-18 FDG PET/CT for Preoperative Lymph Node Staging in Newly Diagnosed Bladder Cancer Patients: A Systematic Review and Meta-Analysis.
    Ha HK, Koo PJ, Kim SJ.
    Oncology; 2018; 95(1):31-38. PubMed ID: 29847834
    [Abstract] [Full Text] [Related]

  • 3. 68Ga-Labeled Prostate-specific Membrane Antigen Ligand Positron Emission Tomography/Computed Tomography for Prostate Cancer: A Systematic Review and Meta-analysis.
    von Eyben FE, Picchio M, von Eyben R, Rhee H, Bauman G.
    Eur Urol Focus; 2018 Sep; 4(5):686-693. PubMed ID: 28753806
    [Abstract] [Full Text] [Related]

  • 4. Diagnostic accuracy of F18 flucholine PET/CT for preoperative lymph node staging in newly diagnosed prostate cancer patients; a systematic review and meta-analysis.
    Kim SJ, Lee SW.
    Br J Radiol; 2019 Sep; 92(1101):20190193. PubMed ID: 31265330
    [Abstract] [Full Text] [Related]

  • 5. Diagnostic Accuracy of 64Copper Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography for Primary Lymph Node Staging of Intermediate- to High-risk Prostate Cancer: Our Preliminary Experience.
    Cantiello F, Gangemi V, Cascini GL, Calabria F, Moschini M, Ferro M, Musi G, Butticè S, Salonia A, Briganti A, Damiano R.
    Urology; 2017 Aug; 106():139-145. PubMed ID: 28438628
    [Abstract] [Full Text] [Related]

  • 6. How accurate is 68Gallium-prostate specific membrane antigen positron emission tomography / computed tomography (68Ga-PSMA PET/CT) on primary lymph node staging before radical prostatectomy in intermediate and high risk prostate cancer? A study of patient- and lymph node- based analyses.
    Erdem S, Simsek DH, Degirmenci E, Aydin R, Bagbudar S, Ozluk Y, Sanli Y, Sanli O, Ozcan F.
    Urol Oncol; 2022 Jan; 40(1):6.e1-6.e9. PubMed ID: 34400066
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. The role of 18F-fluciclovine PET in the management of prostate cancer: a systematic review and meta-analysis.
    Kim SJ, Lee SW.
    Clin Radiol; 2019 Nov; 74(11):886-892. PubMed ID: 31358294
    [Abstract] [Full Text] [Related]

  • 13. Prospective Study of the Radiolabeled GRPR Antagonist BAY86-7548 for Positron Emission Tomography/Computed Tomography Imaging of Newly Diagnosed Prostate Cancer.
    Touijer KA, Michaud L, Alvarez HAV, Gopalan A, Kossatz S, Gonen M, Beattie B, Sandler I, Lyaschenko S, Eastham JA, Scardino PT, Hricak H, Weber WA.
    Eur Urol Oncol; 2019 Mar; 2(2):166-173. PubMed ID: 31017093
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Prostate-Specific Membrane Antigen PET/CT Combined with Sentinel Node Biopsy for Primary Lymph Node Staging in Prostate Cancer.
    Hinsenveld FJ, Wit EMK, van Leeuwen PJ, Brouwer OR, Donswijk ML, Tillier CN, Vegt E, van Muilekom E, van Oosterom MN, van Leeuwen FWB, van der Poel HG.
    J Nucl Med; 2020 Apr; 61(4):540-545. PubMed ID: 31562222
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. A prospective randomized multicentre study of the impact of gallium-68 prostate-specific membrane antigen (PSMA) PET/CT imaging for staging high-risk prostate cancer prior to curative-intent surgery or radiotherapy (proPSMA study): clinical trial protocol.
    Hofman MS, Murphy DG, Williams SG, Nzenza T, Herschtal A, Lourenco RA, Bailey DL, Budd R, Hicks RJ, Francis RJ, Lawrentschuk N.
    BJU Int; 2018 Nov; 122(5):783-793. PubMed ID: 29726071
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Lymph node staging with fluorine-18 prostate specific membrane antigen 1007-positron emission tomography/computed tomography in newly diagnosed intermediate- to high-risk prostate cancer using histopathological evaluation of extended pelvic node dissection as reference.
    Hermsen R, Wedick EBC, Vinken MJM, van Kalmthout LWM, Küsters-Vandevelde HVN, Wijers CHW, Somford DM, van Basten JA.
    Eur J Nucl Med Mol Imaging; 2022 Sep; 49(11):3929-3937. PubMed ID: 35543733
    [Abstract] [Full Text] [Related]

  • 20. Direct comparison of choline PET/CT and MRI in the diagnosis of lymph node metastases in patients with prostate cancer.
    Huang SM, Yin L, Yue JL, Li YF, Yang Y, Lin ZC.
    Medicine (Baltimore); 2018 Dec; 97(50):e13344. PubMed ID: 30557983
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 31.